



Aurobindo Pharma receives Swissmedic approval for Cefepime for Injection

Aurobindo Pharma Limited is pleased to announce that it has received approval from Swissmedic, Government of Switzerland for the license of Cefepime APL for Injection 1g and 2g.

Cefepime APL for Injection 1g and 2g falls under the anti-beta-lactam segment and is indicated for Moderate to severe pneumonia, septicaemia, UTI, skin & skin structure infections, intra-abdominal infections

This is Aurobindo's second product approval from Swissmedic.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 100 countries..

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com